Aptargroup Stock Price, News & Analysis

AptarGroup, Inc. (NYSE:ATR) reported a 9% increase in Q3 2021 sales, reaching $825 million, mainly from strong performance in Beauty + Home and Food + Beverage. Adjusted earnings per share (EPS) were $0.94, down from $1.01 a year ago, due to restructuring and investment losses. The Pharma segment experienced slight sales declines, impacted by lower demand in prescription markets. The company completed acquisitions enhancing its capabilities in medical and digital solutions. Looking ahead, EPS is projected between $0.88 and $0.96 for Q4, with focus on cost containment amid rising inflation.

AptarGroup, Inc. (NYSE:ATR) announced that its patented Cartridge Pump System (CPS) has been reviewed by the U.S. FDA for use in Oyster Point Pharma's TYRVAYA™ Nasal Spray, the first FDA-approved nasal treatment for dry eye disease. This approval marks a significant milestone, confirming Aptar's expertise in drug delivery solutions. The CPS is designed for multidose delivery of both preserved and non-preserved formulations, aiding in the treatment of symptoms associated with dry eye disease, impacting approximately 38 million adults in the U.S.

AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, with a payment date set for November 17, 2021. Shareholders of record as of October 27, 2021, are eligible for this dividend. The company will also host a conference call on October 29, 2021, at 8:00 a.m. CT to discuss its third quarter results. Aptar, headquartered in Crystal Lake, Illinois, specializes in drug delivery and consumer product dispensing solutions.

AptarGroup, Inc. (NYSE: ATR) will host a virtual Capital Markets Day on September 10, 2021, starting at 9:00 a.m. EDT. Senior executives will present and participate in a Q&A session. Interested parties can access the event via the Investor Relations page. A replay will be available for 30 days post-event. Aptar is a leader in drug delivery and consumer product dispensing, operating in various markets such as pharmaceutical and beauty, with a workforce of 13,000 across 20 countries.

AptarGroup, Inc. (NYSE: ATR) announced the passing of Dr. Joanne Smith, a long-time member of its Board of Directors, who served since 1999. Dr. Smith was also the Chairwoman of the Corporate Governance Committee and was revered for her deep market insights and leadership style. Her contributions significantly impacted Aptar's success over the past 22 years, as noted by Chairman George Fotiades and President & CEO Stephan B. Tanda. The company appreciates her guidance and expresses deep gratitude for her commitment.

AptarGroup, Inc. (NYSE: ATR) has successfully acquired a majority stake of approximately 64.6% in Voluntis for €8.70 per share. Following this acquisition, Aptar will initiate a mandatory cash tender offer for the remaining shares at the same price. The transaction has received approval from the French Ministry of Economy and is expected to enhance Aptar's position in drug delivery solutions.

The company's board will issue an opinion on the tender offer, guided by an independent expert report. The current management of Voluntis is expected to remain post-acquisition.

AptarGroup, Inc. (ATR) reported second quarter 2021 results, with sales increasing 16% to $811 million, driven by strong core sales growth across segments. Core sales rose by 10%, particularly in Beauty + Home and Food + Beverage. Net income was $55 million, up 32% year-over-year. Earnings per share reached $0.81, a 29% increase. However, cash flow from operations dropped 23% to $176 million, and free cash flow decreased 63%. The company announced a share purchase agreement for Voluntis and a strategic collaboration with YAT. For Q3 2021, Aptar expects gradual improvement in operating results amidst ongoing cost pressures.

AptarGroup, Inc. (NYSE: ATR) has announced its plan to acquire 80% of Weihai Hengyu Medical Products Co., Ltd., a notable Chinese manufacturer of elastomeric and plastic components for injectable drug delivery. This strategic investment aims to enhance Aptar's capabilities in high-growth markets like China while responding to local market demands. The acquisition is expected to close by the end of Q3 2021 and is not projected to materially impact adjusted earnings per share for 2021 or 2022. This move aligns with Aptar's ongoing strategy to strengthen its position in the injectable drug delivery market.